In contrast, no significant differences were observed between the GLP-1-RA group and the placebo group in the percentage of patients who had an improvement in liver fibrosis stage without worsening of NASH (pooled random-effects odds ratio 1.50, 95% CI 0.98–2.28; Z-test = 1.86, p = 0.06; I2 = 0%). This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.